- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07940933
Niacin and Selenium Combination Therapy in Patients With Septic Shock (NISE-1)
Combination Therapy of Niacin and Selenium in Patients With Septic Shock (Phase IIa Single Center Double-blind Randomized Controlled Trial)
This study will test whether adding niacin, a form of vitamin B3, and selenium, a mineral, to standard treatment improves organ function in adults with septic shock. It will also assess the safety of this combination.
The study plans to enroll 148 patients aged 19 years or older in the emergency intensive care unit at Seoul National University Hospital in South Korea. Participants will be assigned by chance to one of two groups, with an equal chance of receiving either niacin plus selenium or placebo infusions. The placebo infusions use saline and glucose (sugar) solutions and do not contain the study drugs. All participants will receive standard treatment for septic shock.
Study treatments will be given through a vein twice a day during the first week of hospitalization. Participants and the researchers assessing outcomes will not know which treatment each participant receives. The study pharmacist and a designated team that prepares and gives the infusions will know the treatment assignments.
The main comparison will be organ function on the seventh day of hospitalization, measured using the Sequential Organ Failure Assessment (SOFA) score. This score measures how well several organs are working. Researchers will also compare survival at 28 and 90 days, time spent in intensive care, and time on a breathing machine. Blood samples will be collected at enrollment, approximately 72 hours later, and on study day 7 to measure niacin and selenium levels and biomarkers related to antioxidant activity and oxidative stress. Possible side effects will be monitored through daily assessments and blood tests.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Oxidative stress and dysregulated inflammatory responses contribute to tissue injury and organ dysfunction in septic shock. The rationale for combining niacin and selenium is to enhance intracellular antioxidant defenses through complementary effects on the glutathione redox cycle.
Preclinical experiments showed that niacin increased glutathione reductase activity and selenium increased glutathione peroxidase activity. Combined treatment reduced hydrogen peroxide levels, attenuated lung injury, and improved survival in rat models of sepsis. These findings provide a biological basis for evaluating the combination as an adjunctive treatment in patients with septic shock.
The study hypothesis is that combined niacin and selenium treatment during the acute phase of septic shock may reduce oxidative and inflammatory injury and thereby limit organ dysfunction. This study is intended to provide preliminary clinical evidence on efficacy and safety and to inform the planning of a subsequent multicenter trial.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: WOON YONG KWON, MD, PhD
- Número de teléfono: 82-2-2072-0326
- Correo electrónico: kwy711@hanmail.net
Copia de seguridad de contactos de estudio
- Nombre: Hayoung Kim, MD, PhD
- Número de teléfono: 82-2-2072-3257
- Correo electrónico: mogu13@naver.com
Ubicaciones de estudio
-
-
-
Seoul, Corea del Sur, 03080
- Seoul National University Hospital
-
Contacto:
- WOON YONG KWON, MD, PhD
- Número de teléfono: 82-2-2072-0326
- Correo electrónico: kwy711@hanmail.net
-
Contacto:
- Hayoung Kim, MD, PhD
- Número de teléfono: 82-2-2072-3257
- Correo electrónico: mogu13@naver.com
-
Investigador principal:
- WOON YONG KWON, MD, PhD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 19 years or older, irrespective of sex or race.
- Admission to the emergency intensive care unit at Seoul National University Hospital with septic shock, defined by all of the following:
Infection-related organ dysfunction with a Sequential Organ Failure Assessment (SOFA) score of 2 or greater.
Sepsis-induced hypotension requiring vasopressors to maintain a mean arterial pressure of 65 mmHg or higher.
A blood lactate concentration of 2 mmol/L or higher despite administration of 30 mL/kg of intravenous crystalloid fluid. If this volume cannot be administered because of pulmonary edema, heart failure, chronic renal failure, or other clinical limitations, the maximum clinically tolerated volume of crystalloid fluid must have been administered.
Written informed consent provided by the participant or an authorized representative.
Informed consent and randomization completed within 24 hours after the diagnosis of septic shock.
Exclusion Criteria:
- Pregnancy or breastfeeding.
- Age younger than 19 years.
- Cardiac arrest requiring cardiopulmonary resuscitation before admission to the emergency intensive care unit.
- Expected death within 72 hours because of the severity of illness.
- Patients for whom aggressive treatment is not being provided in accordance with an advance directive.
- Known pre-existing liver failure with a Child-Pugh score of 10 or greater.
- Lack of informed consent from the participant or an authorized representative.
- Any other condition or circumstance that, in the investigator's judgment, makes participation in the trial inappropriate.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Niacin plus Selenium
Participants receive intravenous niacin plus selenium every 12 hours during the first week of hospitalization, in addition to standard care for septic shock. |
Niacin (nicotinic acid) is supplied by Christmas Co., Ltd. (South Korea) as V-Tree Inj., a solution for injection containing 50 mg of niacin per 1 mL ampoule. A dose of 100 mg will be diluted with 0.9% sodium chloride solution to a final volume of 50 mL and administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization. Selenium is supplied as selenase T pro injectione (biosyn Arzneimittel GmbH, Germany), a solution for injection containing 500 micrograms of selenium as sodium selenite pentahydrate per 10 mL vial (50 micrograms/mL). A dose of 5 micrograms/kg of selenium will be diluted with 5% dextrose solution to a final volume of 50 mL and administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization. |
|
Comparador de placebos: Placebo
Participants receive intravenous placebo infusions of 0.9% sodium chloride and 5% dextrose every 12 hours during the first week of hospitalization, in addition to standard care for septic shock. |
Participants receive 50 mL of 0.9% sodium chloride solution as the placebo for niacin. The solution is administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization. Participants receive 50 mL of 5% dextrose solution as the placebo for selenium. The solution is administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Sequential Organ Failure Assessment (SOFA) Score on Hospital Day 7
Periodo de tiempo: Hospital day 7
|
Total Sequential Organ Failure Assessment (SOFA) score assessed on hospital day 7. The SOFA score evaluates six organ systems: respiratory, coagulation, liver, cardiovascular, central nervous system, and renal. Each component is scored from 0 to 4, giving a total score of 0 to 24; higher scores indicate more severe organ dysfunction. The day-7 score will be compared between groups using analysis of covariance, with adjustment for the SOFA score at admission. |
Hospital day 7
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
28-Day Survival
Periodo de tiempo: From hospital admission (hospital day 0) through day 28
|
Survival will be assessed from hospital admission, defined as hospital day 0, through day 28. The probability of survival at day 28 will be estimated using the Kaplan-Meier method. |
From hospital admission (hospital day 0) through day 28
|
|
90-Day Survival
Periodo de tiempo: From hospital admission (hospital day 0) through day 90
|
Survival will be assessed from hospital admission, defined as hospital day 0, through day 90. The probability of survival at day 90 will be estimated using the Kaplan-Meier method. |
From hospital admission (hospital day 0) through day 90
|
|
Length of Intensive Care Unit Stay
Periodo de tiempo: From hospital admission (hospital day 0) through hospital day 90
|
Length of stay in the intensive care unit, measured in days, during follow-up through hospital day 90. |
From hospital admission (hospital day 0) through hospital day 90
|
|
Duration of Mechanical Ventilation
Periodo de tiempo: From hospital admission (hospital day 0) through hospital day 90
|
Duration of mechanical ventilation, measured in days, during follow-up through hospital day 90. |
From hospital admission (hospital day 0) through hospital day 90
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Pharmacologic, Antioxidant, and Mechanistic Biomarkers
Periodo de tiempo: At enrollment, 72 hours (±6 hours), and day 7
|
Blood samples will be analyzed to assess the biological effects of niacin and selenium treatment, including circulating niacin and selenium levels and biomarkers related to antioxidant activity, redox balance, and oxidative stress. Planned analyses include glutathione reductase activity, glutathione peroxidase activity, and hydrogen peroxide levels. |
At enrollment, 72 hours (±6 hours), and day 7
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: WOON YONG KWON, MD, PhD, Seoul National University Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Infecciones
- Septicemia
- Síndrome de Respuesta Inflamatoria Sistémica
- Inflamación
- Choque
- Condiciones Patológicas, Signos y Síntomas
- Choque séptico
- Piridina
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Químicos inorgánicos
- Elementos
- Calcógenos
- Minerales
- Ácidos, heterocíclicos
- Ácidos nicotínicos
- Niacina
- Selenio
Otros números de identificación del estudio
- SNUH-NISE-2026
- 2509-096-1679 (Otro identificador: Seoul National University Hospital Institutional Review Board)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
De-identified individual participant data that underlie the results reported in the primary publication may be shared with qualified researchers upon reasonable request, subject to review and approval by the principal investigator and applicable institutional and ethical requirements. Data will be shared only in a manner that protects participant confidentiality and privacy.
Marco de tiempo para compartir IPD
De-identified individual participant data and supporting information will be available beginning 6 months after publication of the primary study results and for 3 years thereafter.
Criterios de acceso compartido de IPD
De-identified individual participant data that underlie the results reported in the primary publication, together with the study protocol and statistical analysis plan, may be made available to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the principal investigator and must comply with applicable institutional and ethical requirements. Approved data will be provided through a secure data-sharing method after execution of any required data use agreement.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .